Perifosine Induces Cell Apoptosis in Human Osteosarcoma Cells: New Implication for Osteosarcoma Therapy?

Cell Biochemistry and Biophysics

Volumn 65, Issue 2, 2013, Pages 217-227

  Yao, Chen ^a   Wei, Jian jun ^a   Wang, Zu yu ^a   ding, Hui min ^a   Li, Dong ^a   Yan, Shi chang ^a   Yang, Yong jiang ^a   Gu, Zhang ping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Chemotherapy; JNK; Osteosarcoma cells; p53; Perifosine; Survivin

Indexed keywords

EID: 84874275540     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9423-5     Document Type: Article

References (44)

1. Ham, S. J., Schraffordt Koops, H., van der Graaf, W. T., van Horn, J. R., Postma, L., & Hoekstra, H. J. (1998). Historical, current and future aspects of osteosarcoma treatment. European Journal of Surgical Oncology, 24, 584-600.
2. Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979). Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer, 43, 2163-2177.
3. Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. K. (2003). Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Molecular Cancer Therapeutics, 2, 1093-1103.
4. Ruiter, G. A., Zerp, S. F., Bartelink, H., van Blitterswijk, W. J., & Verheij, M. (1999). Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Research, 59, 2457-2463.
5. Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., et al. (2011). Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Molecular Cancer Therapeutics, 9, 963-975.
6. Crul, M., Rosing, H., de Klerk, G. J., Dubbelman, R., Traiser, M., Reichert, S., et al. (2002). Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. European Journal of Cancer, 38, 1615-1621.
7. van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., et al. (2004). A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clinical Cancer Research, 10, 7450-7456.
8. Fei, H. R., Chen, G., Wang, J. M., & Wang, F. Z. (2010). Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology, 62, 449-460.
9. Papa, V., Tazzari, P. L., Chiarini, F., Cappellini, A., Ricci, F., Billi, A. M., et al. (2008). Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 22, 147-160.
10. Chiarini, F., Del Sole, M., Mongiorgi, S., Gaboardi, G. C., Cappellini, A., Mantovani, I., et al. (2008). The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 22, 1106-1116.
11. Sun, H., Yu, T., & Li, J. (2011). Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition. Cancer Letters, 310, 118-128.
12. Kumar, A., Fillmore, H. L., Kadian, R., Broaddus, W. C., Tye, G. W., & van Meter, T. E. (2009). The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. Molecular Cancer Research, 7, 1813-1821.
13. Rahmani, M., Reese, E., Dai, Y., Bauer, C., Payne, S. G., Dent, P., et al. (2005). Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research, 65, 2422-2432.
14. Paoloni, M. C., Mazcko, C., Fox, E., Fan, T., Lana, S., Kisseberth, W., et al. (2011). Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: A comparative oncology study in dogs. PLoS ONE, 5, e11013.
15. Zhang, B., Shi, Z. L., Liu, B., Yan, X. B., Feng, J., & Tao, H. M. (2010). Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: The role of Akt and nuclear factor-kappaB. Anti-Cancer Drugs, 21, 288-296.
16. Zhou, R., Zhang, Z., Zhao, L., Jia, C., Xu, S., Mai, Q., et al. (2010). Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells. Journal of Orthopaedic Research, 29, 846-852.
17. Jin, S., Pang, R. P., Shen, J. N., Huang, G., Wang, J., & Zhou, J. G. (2007). Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis, 12, 1317-1326.
18. Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., et al. (2006). Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107, 4053-4062.
19. Altieri, D. C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 22, 8581-8589.
20. Altieri, D. C., & Marchisio, P. C. (1999). Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Laboratory Investigation, 79, 1327-1333.
21. Altieri, D. C. (2003). Validating survivin as a cancer therapeutic target. Nature Reviews Cancer, 3, 46-54.
22. Trieb, K., Lehner, R., Stulnig, T., Sulzbacher, I., & Shroyer, K. R. (2003). Survivin expression in human osteosarcoma is a marker for survival. European Journal of Surgical Oncology, 29, 379-382.
23. Wu, Y. F., Liang, X. J., Liu, Y. Y., Gong, W., Liu, J. X., Wang, X. P., et al. (2010). +Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma, 57, 501-506.
24. Zhang, H. Z., Wang, Y., Gao, P., Lin, F., Liu, L., Yu, B., et al. (2006). Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biology & Therapy, 5, 1457-1461.
25. Zou, J., Gan, M., Mao, N., Zhu, X., Shi, Q., & Yang, H. (2010). Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Archives of Medical Research, 41, 162-169.
26. Fortugno, P., Beltrami, E., Plescia, J., Fontana, J., Pradhan, D., Marchisio, P. C., et al. (2003). Regulation of survivin function by Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 100, 13791-13796.
27. Merrill, A. H., Jr, van Echten, G., Wang, E., & Sandhoff, K. (1993). Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. Journal of Biological Chemistry, 268, 27299-27306.
28. Charles, A. G., Han, T. Y., Liu, Y. Y., Hansen, N., Giuliano, A. E., & Cabot, M. C. (2001). Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemotherapy and Pharmacology, 47, 444-450.
29. Vinall, R. L., Hwa, K., Ghosh, P., Pan, C. X., Lara, P. N., Jr, & de Vere White, R. W. (2007). Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clinical Cancer Research, 13, 6204-6216.
30. Ruiter, G. A., Verheij, M., Zerp, S. F., & van Blitterswijk, W. J. (2001). Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. International Journal of Radiation Oncology Biology Physics, 49, 415-419.
31. Vivanco, I., & Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer, 2, 489-501.
32. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery, 4, 988-1004.
33. Garcia-Echeverria, C., & Sellers, W. R. (2008). Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 27, 5511-5526.
34. LoPiccolo, J., Granville, C. A., Gills, J. J., & Dennis, P. A. (2007). Targeting Akt in cancer therapy. Anti-Cancer Drugs, 18, 861-874.
35. Lu, Y., Wang, H., & Mills, G. B. (2003). Targeting PI3K-AKT pathway for cancer therapy. Reviews in Clinical & Experimental Hematology, 7, 205-228.
36. Gills, J. J., & Dennis, P. A. (2009). Perifosine: Update on a novel Akt inhibitor. Current Oncology Reports, 11, 102-110.
37. Hennessy, B. T., Lu, Y., Poradosu, E., Yu, Q., Yu, S., Hall, H., et al. (2007). Pharmacodynamic markers of perifosine efficacy. Clinical Cancer Research, 13, 7421-7431.
38. Wang, Q., Wang, X., Hernandez, A., Hellmich, M. R., Gatalica, Z., & Evers, B. M. (2002). Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. Journal of Biological Chemistry, 277, 36602-36610.
39. Tazzari, P. L., Tabellini, G., Ricci, F., Papa, V., Bortul, R., Chiarini, F., et al. (2008). Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Research, 68, 9394-9403.
40. Simbulan-Rosenthal, C. M., Rosenthal, D. S., Luo, R., & Smulson, M. E. (1999). Poly(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells. Cancer Research, 59, 2190-2194.
41. Schuler, M., Bossy-Wetzel, E., Goldstein, J. C., Fitzgerald, P., & Green, D. R. (2000). p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. Journal of Biological Chemistry, 275, 7337-7342.
42. Workman, P., & Powers, M. V. (2007). Chaperoning cell death: A critical dual role for Hsp90 in small-cell lung cancer. Nature Chemical Biology, 3, 455-457.
43. Whitesell, L., & Lindquist, S. L. (2005). HSP90 and the chaperoning of cancer. Nature Reviews Cancer, 5, 761-772.
44. Neckers, L. (2002). Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends in Molecular Medicine, 8, S55-61.